
Parabilis Medicines, Inc.
Sector
Healthcare
Filed
May 19, 2026
About
Parabilis Medicines, Inc.
Parabilis Medicines is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease.
We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
Our lead product candidate, zolucatetide, is, to our knowledge, the first and only investigational therapy that inhibits the b-catenin:TCF interaction, the critical downstream node of the Wnt/b-catenin pathway.
Parabilis Medicines, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1/A | May 27, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | May 19, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS | Apr 2, 2026 | [Cover] Draft Registration Statement |
| D | Dec 2, 2022 | Notice of Exempt Offering of Securities |
| D | Jan 5, 2021 | Notice of Exempt Offering of Securities |
| D/A | May 16, 2018 | Filing |
| D | Feb 14, 2018 | Notice of Exempt Offering of Securities |
| D/A | Aug 22, 2017 | Filing |
| D | Jun 7, 2016 | Notice of Exempt Offering of Securities |
| D | Nov 13, 2015 | Notice of Exempt Offering of Securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Mathai Mammen, M.D., Ph.D.
Chairman, Chief Executive Officer and President
Fawzi Benzaghou, M.D.
Chief Medical Officer
Helen Ho, Ph.D.
Chief Business and Strategy Officer
Thomas Kotarakos
Chief Financial Officer
Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Teresa Jurgensen, J.D.
General Counsel
Alexis Borisy
Director
Edward Fitzgerald
Director
Rick Klausner, M.D.
Director
Alan M. Sebulsky
Director